Sun Pharmaceutical Industries sees API sales slide in Q3

By Gareth Macdonald contact

- Last updated on GMT

Sun Pharmaceutical Industries Ltd. saw lower active pharmaceutical ingredient (API) revenue in the third quarter of fiscal 2017.

The Indian manufacturer’s drug ingredients business generated revenue of INR3.66bn ($54.7m) in the three months to December 31 2016, down 17% on the equivalent quarter in the previous fiscal year.

Sun did not say what had caused API revenues to fall, but did say it had increased the volume of drug ingredients it supplies to its own generic pharmaceutical business.

Related news

Related products

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Related suppliers